You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

66 Results
Document
Jan 2025
Document
Jan 2025
Regimen
Cancer Type:
Central Nervous System
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    vorasidenib - For the treatment of Grade 2 astrocytoma or oligodendroglioma in patients with a susceptible IDH1 mutation or IDH2 mutation following surgery, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
vorasidenib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2026
Drug
Other Name(s): Zolinza®
Quick Link(s): Drug Monograph, Patient Info Sheet
Updated
Mar 2026
Drug
Other Name(s): Voranigo™
Quick Link(s): Drug Monograph, Patient Info Sheet
Updated
Mar 2026

Pages